Study: Low-dose aspirin may not lessen cardiovascular disease risk

LONDON According to a meta-analysis published last week in the medical journal BMJ, low-dose aspirin may not be effective in lowering cardiovascular disease risk in the diabetes population.

The meta-analysis included six randomized trials of aspirin compared with placebo or no aspirin in people with diabetes and no pre-existing heart disease, encompassing more than 10,000 participants.

Researchers found no statistically significant reduction in the risk of major cardiovascular events when aspirin was compared with placebo across these six studies.

Researchers concluded that a clear benefit of aspirin in the primary prevention of major cardiovascular events in people with diabetes has yet to be clinically established.